Conatus Pharmaceuticals Completes Enrollment in Phase 2n Study

Conatus Pharmaceuticals said late Monday it has completed enrollment in a phase 2b study of emricasan in approximately 330 patients with biopsy-confirmed nonalcoholic steatohepatitis and stage 1 to 3 fibrosis. The primary endpoint of the study is a biopsy-based improvement in fibrosis by at least one stage compared to placebo using NASH CRN without worsening of steatohepatitis.

Secondary endpoints include resolution of steatohepatitis without worsening of fibrosis, nonalcoholic fatty liver disease activity score and its components (steatosis, lobular inflammation, and ballooning), collagen and fat content by biopsy, key serum biomarkers, and health-related quality of life, as well as safety and tolerability. The study is expected to produce top-line results in the first half of 2019.

Leave a Comment